Probenecid | CLtotal | CLbile,p | CLbile,h | CLuptake | fp | fh |
---|---|---|---|---|---|---|
μmol/min/kg | ml/min/kg | |||||
0 | 14.7 ± 1.0 | 9.43 ± 0.33 | 13.1 ± 0.3 | 11.9 ± 0.8 | 0.642 ± 0.026 | 0.217 ± 0.010 |
1.1 | 9.83 ± 0.19 | 5.43 ± 0.13 | 8.65 ± 0.64 | 6.75 ± 0.35 | 0.574 ± 0.005 | 0.287 ± 0.023 |
2.2 | 8.18 ± 0.93 | 4.59 ± 0.10 | 6.98 ± 0.19 | 8.12 ± 0.41 | 0.590 ± 0.005 | 0.237 ± 0.019 |
3.3 | 6.94 ± 0.15 | 2.72 ± 0.11 | 6.29 ± 0.49 | 4.82 ± 0.23 | 0.539 ± 0.013 | 0.333 ± 0.022 |
4.4 | 6.37 ± 0.81 | 2.27 ± 0.13 | 6.14 ± 0.29 | 5.10 ± 0.35 | 0.582 ± 0.007 | 0.250 ± 0.024 |
Both methotrexate (0.164 μmol/min/kg) and probenecid were infused intravenously at the indicated infusion rates. The steady-state methotrexate concentration in plasma, bile, and liver were determined, and pharmacokinetic parameters (mean ± S.E. of four or five rats) were calculated.